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lung cancer, based on 2 suc-
cessive 18F-fludeoxyglucose
positron emission tomogra-
phy scans. The results
showed that it is feasible to
determine a threshold value
of the average effective
radiosensitivity in the pri-
mary gross target volume but
not in the lymph node grossReprint requests to: Iuliana Toma-Dasu,
Physics, Stockholm University and Karolinska
76 Stockholm, Sweden. Tel: (þ46) 8-5177 48
Dasu@ki.se
Supported by the QuIC-ConCePT project,
EFPI A companies and the Innovative Medici
taking under Grant Agreement No. 115151;
Int J Radiation Oncol Biol Phys, Vol. 91, No. 2
0360-3016/$ - see front matter  2015 Elsevie
http://dx.doi.org/10.1016/j.ijrobp.2014.10.012Objective: To assess early tumor responsiveness and the corresponding effective
radiosensitivity for individual patients with non-small cell lung cancer (NSCLC) based
on 2 successive 18F-fludeoxyglucose positron emission tomography (FDG-PET) scans.
Methods and Materials: Twenty-six NSCLC patients treated in Maastricht were
included in the study. Fifteen patients underwent sequential chemoradiation therapy,
and 11 patients received concomitant chemoradiation therapy. All patients were imaged
with FDGbefore the start and during the secondweek of radiation therapy. The sequential
images were analyzed in relation to the dose delivered until the second image. An
operational quantity, effective radiosensitivity, aeff, was determined at the voxel level.
Correlations were sought between the average aeff or the fraction of negative aeff values
and the overall survival at 2 years. Separate analyseswere performed for the primarygross
target volume (GTV), the lymph node GTV, and the clinical target volumes (CTVs).
Results: Patients receiving sequential treatment could be divided into responders and
nonresponders, using a threshold for the average aeff of 0.003 Gy
1 in the primary
GTV, with a sensitivity of 75% and a specificity of 100% (P<.0001). Choosing the
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these patients into re-
sponders and nonresponders.and a specificity of 100% (P<.0001). Good prognostic potential was maintained for pa-
tients receiving concurrent chemotherapy. For lymph node GTV, the correlation had low
statistical significance. A cross-validation analysis confirmed the potential of themethod.
Conclusions: Evaluation of the early response in NSCLC patients showed that it is
feasible to determine a threshold value for effective radiosensitivity corresponding to
good response. It also showed that a threshold value for the fraction of negative aeff could
also be correlated with poor response. The proposed method, therefore, has potential to
identify candidates for more aggressive strategies to increase the rate of local control
and also avoid exposing to unnecessary aggressive therapies the majority of patients re-
sponding to standard treatment.  2015 Elsevier Inc.Introduction
Progress during recent decades in imaging with positron
emission tomography (PET) has improved cancer diagnosis
and prognosis by increasing the accuracy of determining and
delineating target structures, providing also the tools for indi-
vidualized 4-dimensionalebased radiation therapy (RT) (1).
Furthermore, PET imaging has also been used for detecting the
residual metabolically active tumor mass after treatment and
hence for posttreatment evaluation of its effectiveness (2, 3).
For lung cancer patients in particular, contrast-enhanced
computed tomography (CT) imaging in combination with
18F-fludeoxyglucose (FDG) PET scans is the most widely
used imaging technique for staging and delineating the
targets (4, 5). Extensive work has been done on assessing the
predictive potential of pretreatment FDG-PET and the
prognostic potential of imaging after the completion of
chemoradiation therapy, radiation therapy, or both for poor
treatment response (6-12). Fewer studies, however, have
investigated the potential of assessing the response of the
target to the treatment by monitoring the changes in FDG
uptake at an early timepoint during the course of chemo-
radiation therapy (13-17). A recent study (18) showed that a
decrease in metabolic activity of the primary tumor
calculated as the difference between the averaged standar-
dized uptake value (SUV) before the start of the treatment
and the average SUV determined as early as the second week
of treatment was predictive of 2-year overall survival.
The aim of the present study was to perform a system-
atic evaluation of the tumor response for non-small cell
lung cancer (NSCLC) patients previously treated with
chemoradiation therapy to determine the potential of
repeated FDG-PET CT images for early identification of
responders and nonresponders and thus for identifying
patients who might benefit from treatment adaptation.Methods and Materials
Patient treatment protocol and PET-CT image
acquisition
Twenty-six NSCLC patients treated with radical
radiation therapy at the Department of Radiation Oncology(MAASTRO clinic), Maastricht University Medical Center,
The Netherlands were included in the analysis (18-20). Patients
underwent radiation therapy with either sequential or concur-
rent chemotherapy. Patients treatedwith the sequential regimen
received 3 cycles of cisplatin-gemcitabine before starting the
radiation treatment, and patients treated in the concurrent
regimen received 1 cycle of cisplatin-vinorelbine followed by
concomitant chemoradiation therapy with the remaining 2 cy-
cles of chemotherapy delivered during radiation treatment. For
the sequential group, the radiation therapy delivered 2 fractions
of 1.8 Gy per day either up to a total prescribed maximum dose
of 79.2 Gy or up to the limit of the tolerated normal tissue
toxicity. For the concurrent group, a dose escalation protocol
was chosenwith 30 fractions of 1.5Gy2 times per daydelivered
first, followed by 2 Gy fractions once per day up to either the
prescribedmaximum dose of 69 Gy or to normal tissue toxicity
limit. The relevant patient characteristics are listed in Table 1.
All patients included in this study were imaged in radia-
tion therapy position with FDG-PETCT before the treatment
and during the second week of radiation treatment, the time
interval ranging from 8 to 13 days. The pretreatment
FDG-PET CT images were acquired after 1 cycle and 3
cycles of chemotherapy in the concurrent and sequential
regimens, respectively. The PET CT images were acquired
with a Biograph 40 PET camera (Siemens Medical
Solutions). The injected FDG activity inMBqwas calculated
as 4 times the bodyweight inKgplus 20 additionalMBq (18).
RayStation and image registration
The 2 available datasets of reconstructed PET-CT images
for each patient were imported in a research version of
RayStation (RaySearch Laboratories AB). A voxel-to-voxel
mapping was achieved by registering the 2 PET-CT images
acquired at the 2 different timepoints, after which a
PET-on-PET voxel interpolation was performed. A hybrid
deformable registration method, which combines an
image-based algorithm and one that uses anatomic infor-
mation provided by the contoured datasets, was used (21).
Effective tumor radiation sensitivity
The variations of the FDG SUV in the target volume of the
paired PET image datasets were analyzed. It was assumed
Table 1 Characteristics of the patients in the study
No. TNM Stage No. of fx at PET2 Dose/fx (Gy) OS at 2 years aeff , Gy
1 faeff , %
Radiation therapy þ sequential chemotherapy
1 T2N2M0 IIIa 13 1.8 1 0.006 28
2 T3N3M0 IIIb 13 1.8 0 0.001 41
3 T3N2M0 IIIa 13 1.5 1 0.012 19
4 T2N3M0 IIIb 13 1.5 1 0.001 55
5 T1N3M0 IIIb 13 1.5 1 0.034 0
6 T2N2M0 IIIa 19 1.8 0 0.000 47
7 T4N2M0 IIIb 15 1.5 0 0.003 38
8 T4N2M0 IIIb 11 1.5 0 0.003 63
9 T1N2M0 IIIa 17 1.5 1 0.015 2
10 T2N2M0 IIIa 13 1.8 0 0.006 73
11 T2N2M0 IIIa 11 1.5 1 0.029 15
12 T4N0M0 IIIb 11 1.5 1 0.011 25
13 T2N3M0 IIIb 12 1.5 0 0.008 65
14 T4N2Mn.i. IIIb 13 1.8 0 0.007 84
15 T2N2M0 IIIa 13 1.8 1 0.001 49
Radiation therapy þ concurrent chemotherapy
16* T1N0M0 Ia 12 1.5 1 0.020 20
17* T3N2M0 IIIa 12 1.5 1 0.022 12
18 T2N2M0 IIIa 13 1.5 1 0.008 28
19 T2N2M0 IIIa 8 1.5 0 0.011 76
20 T4N0M0 IIIb 17 1.5 1 0.010 11
21 T4N3M0 IIIb 17 1.5 1 0.001 55
22 T1N2M0 IIIa 11 1.5 1 0.007 23
23 T2N3M0 IIIb 13 1.5 1 0.005 32
24 T2N2M0 IIIa 17 1.5 0 0.004 33
25 T1N2M0 IIIa 11 1.5 0 0.001 32
26 T2N3M0 IIIb 10 1.5 0 0.006 73
27 T3N0M0 IIb 11 1.5 1 0.008 24
Abbreviations: fx Z fractions; OS Z overall survival; PET2 Z second positron emission tomography scan.
* 16 and 17 refer to the same patient with two primary tumors.
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a change in the density of functional clonogenic cells
resulting from cell kill by radiation. An operational
parameter for radiosensitivity, aeff, can be determined from
the quotient of the 2 PET image values and the planned
delivered dose distribution under the linear quadratic













where PET1(r) and PET2(r) are the SUV values in voxel r
of the PET images acquired before and during the second
week of radiation treatment, and d(r) and n are the dose per
fraction and the number of fractions delivered until the
second PET image. An a=b Z 10 Gy was assumed for the
tumor cells.
A schematic illustration of the method is given in
Figure 1.
This voxel-based analysis in the target volume leads to a
distribution of effective radiosensitivity values for which one
could calculate the average effective radiation sensitivity,aeff , and the fraction of voxels having negative effective
radiation sensitivity, faeff .
Statistical analysis and cross-validation
Correlations were sought between the derived aeff , or the
fraction of negative aeff values in the distribution, faeff , and
the overall patient survival at 2 years. Separate analyses
were performed for the primary gross target volume
(GTVprim), the lymph node GTV (GTVlymph), the primary
clinical target volume (CTVprime), and the lymph node
CTV (CTVlymph). The statistical analysis was done on
subsets of patients depending on the administration of ra-
diation therapy in relation to chemotherapy.
Commercial software, MedCalc, version 13.1.0.0
(MedCalc Software), was used to generate receiver oper-
ating characteristic (ROC) curves to determine the optimal
threshold that would correlate best with the overall 2-year
survival. The optimal criterion was determined as the value
with highest specificity and sensitivity according to the
ROC curve. The accuracy of the prediction was quantified
in terms of area under the curve (AUC). The method
by DeLong and co-authors (23) was selected for the
calculation of the standard error of the AUC.
Fig. 1. Illustration of the method used for the assessment of the tumor response based on 2 successive 8F-fludeoxyglucose
positron emission tomography (FDG-PET) images in relation to the dose delivered by the time of the second FDG-PET
acquisition. The baseline hypothesis is that the FDG uptake in the PET image is proportional with the density of the
clonogenic cells. CT Z computed tomography.
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dependent dataset, the findingswere also subjected to a cross-
validation procedure. Given the small dataset available, the
“leave-one-out” cross-validation method was chosen (24).
An in-house MATLAB version 7.13 (MathWorks, Inc) code
was written to perform the analysis. The leave-one-out
method divides the data into 2 mutually exclusive datasets.
A logistic regression model is fitted on a validation dataset
consisting of the entire dataset minus 1 observation, and the
fitting parameters of the model are used to evaluate the single
observation left outside (the training set). The procedure is
repeated for all the observations in the considered dataset.
The AUC values of the recalculated ROC curves and corre-
sponding P values are reported and reviewed.
Robustness analysis with respect to image
registration
The method for assessing tumor responsiveness to treat-
ment based on 2 successive FDG-PET CT images was
tested for robustness with respect to the registration by
adding a translation error to the transformation matrix of
the CT-to-CT registration. Thus, the calculation of the aeff
values at voxel level was redone for 3 different cases when
the second PET image was rigidly translated with 5 mm in
the anteroposterior direction, the left-right direction, and
the craniocaudal direction, respectively. The test aimed to
check whether aeff and faeff corresponding to the new dis-
tributions of aeff values resulting after the translations
would render similar correlation trends with the overall
patient survival at 2 years, as in the case of no systematic
translations.Results
Identification of tumor response patterns
Figure 2 shows the CT and PET images at the 2 mentioned
timepoints, and the distributions of effective radiosensitiv-
ities derived with equation 1 in the GTVprim for 3 patients
considered representative of the tumor response patterns
identified in the analyzed patient group. The upper panel
shows the case of a patient with lower SUVs in all GTVprim
voxels at the time of the second PET-CT scan, after the
delivery of 13 fractions of 1.5 Gy, in comparison with the
SUVs in the corresponding voxels before the start of
treatment. The resulting values of aeff are all positive,
indicating a decrease of the number of clonogenic cells in
each voxel. The patient was alive 2 years after treatment.
The middle panel shows the case of a patient with a
majority of negative aeff values in the resulting distribution,
who did not survive 2 years after treatment. The lower
panel shows the case of a patient with a more complex
distribution of aeff values, mostly positive, who was alive at
2 years after treatment. The other patients exhibited
distributions of aeff values that were largely encompassed
by these patterns.Average aeff and the fraction of voxels having
negative aeff
Given the resultant distributions of effective radiosensiti-
vities, correlations were sought between the survival at
2 years after chemoradiation therapy and the calculated
Fig. 2. Computed tomographic images, 2 successive positron emission tomographic (PET) images, and the distribution of the
effective radiosensitivity, aeff, in the clinical target volume of the primary tumor (GTVprim) volume for 3 selected patients. The
CTVprim is contoured inwhite and the gross tumor volume of the primary tumor in red. The upper panels show the distributions of
the effective radiosensitivities in a patient with good response to the treatment assessed as survival at the 2-year follow-up visit: a
decrease in the 8F-fludeoxyglucose uptake is noticed in the second PET image compared with the first PET acquisition. The
middle panels correspond to a patient with poor response: the uptake of the tracer in the second PET image shows an increase in
comparison with the first PET image. The lower panels describe a patient with good response: the uptake of the tracer in the
second PET image indicates enhanced tracer perfusion in comparison with the first PET image.
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voxels having negative effective radiation resistance, faeff .
The analysis was performed by stratifying the ensemble
according to the type of chemoradiation therapy (ie con-
current or sequential chemotherapy). The corresponding
values for the aeff and faeff for the patients included in the
analysis are shown in Table 1.
The ROC analysis for the patients treated with RT and
sequential chemotherapy revealed that the method for
dividing the patients into responders and nonresponders
was statistically significant (P<.0001), with a sensitivity of
75% and a specificity of 100%, both when aeff , and faeff
were used as criteria. Thus, all nonresponders were
correctly identified, and 25% of the responders were mis-
identified as nonresponders.
For the patients treated with RT and concurrent
chemotherapy, a sensitivity of 87% with 100% specificity
was found based on aeff , and the analysis was statisticallysignificant (P<.0001). Choosing faeff as a criterion, the
method showed a sensitivity of 75% and a specificity of
100% (P<.001).
These findings are summarized inFigure 3,where theROC
curves show the correlation between aeff and the treatment
outcome and also the correlation between faeff and the treat-
ment outcome for the 2 groups of patients (15 and 12 cases are
included in the sequential and concurrent group, respectively)
in theGTVof the primary tumor. The correspondingAUCand
the P value are indicated on each figure.
A similar analysis was performed for the distribution of
the effective radiosensitivity at voxel level in the GTV of
the involved mediastinal lymph nodes, GTVlymph. The
trends observed for the primary GTV were maintained only
with respect to the specificity of the method, but the sta-
tistical significance in this case was very low (Table 2).
The analysis was extended to include the contribution of
the CTV-to-GTV margins for the primary tumor and the
Volume 91  Number 2  2015 Tumor response evaluation with FDG-PET 381lymph nodes, and the results are also summarized in
Table 2. The correlation of the responsiveness of the node
target volumes with the treatment outcome lacks statistical
significance, as does the distribution of the effective
sensitivity in the CTVs.
Cross-validation and CT translational registration
robustness test
Given the low number of patients available for this study,
the results were subjected to a cross-validation analysis
using the “leave-one-out” method (24). The results of the
cross-validation showed that dividing the patients into good
responders and poor responders based on the assessment of
the effective radiosensitivity rendered statistically signifi-
cant results with a sensitivity and a specificity larger than
75%, only for the patients treated with RT and sequential
chemotherapy, when the fraction of negative radiosensi-
tivities, faeff , was chosen as the selection criterion. The
recalculated AUC value after cross-validation was
approximately 0.86, with a P value equal to 0.0002.Fig. 3. Receiver operating characteristics curves showing th
outcome and also the correlation between the fraction of negative
treatment outcome for the 2 groups of patients receiving radiati
diation therapy and concurrent chemotherapy (c and d). The corr
indicated in each case.As part of the robustness analysis of the described
method to the quality of image registration, aeff distribu-
tions were recalculated after independent rigid translations
of 5 mm in the anteroposterior, craniocaudal, and lateral
directions introduced in the registration matrix for the
2 datasets. The repeated analysis of the new resultant aeff
distributions largely showed the same trends with respect to
the AUC and P values.
Discussion
The FDG-PET method has improved staging and influ-
enced treatment for NSCLC by reducing interobserver
variability in target delineation (25). Pretreatment values
characterizing the uptake of the PET tracer have also
proved to have prognostic values for patients with lung
cancer undergoing surgery (2). PET imaging has also been
used for posttreatment assessment by investigating the
metabolic activity of the residual mass at the end of
treatment (26). Nevertheless, a large but not sufficiently
explored potential of PET lies in characterizing subtlee correlation between the average aeff and the treatment
aeff in the gross tumor volume of the primary tumor and the
on therapy and sequential chemotherapy (a and b) and ra-
esponding area under the curve (AUC) and the P value are
Table 2 Summary of the ROC analysis for various target volumes
Target
ROC analysis based on aeff ROC analysis based on faeff
Sensitivity Specificity AUC P value Criterion Sensitivity Specificity AUC P value Criterion
Radiation therapy þ sequential chemotherapy
GTVprim 75 100 0.92 <.0001 >0.003 75 100 0.89 <.0001 0.3
GTVlymph 67 100 0.72 .2 >0.001 67 100 0.71 .3 0.5
CTVprim 67 100 0.85 .0003 >0.001 67 100 0.86 .0003 0.4
CTVlymph 50 100 0.61 .6 >0.002 50 100 0.75 .1 0.4
Radiation therapy þ concurrent chemotherapy
GTVprim 87 100 0.94 <.0001 >0.004 75 100 0.92 <.0001 0.3
GTVlymph 20 50 0.53 .9 >0.007 80 50 0.55 .8 >0.3
CTVprim 100 75 0.88 .004 >0.005 100 75 0.86 .005 0.6
CTVlymph 80 50 0.53 .9 >0.007 100 25 0.55 .8 >0.2
Abbreviations: AUC Z area under the curve; CTVlymph Z lymph node clinical target volume; CTVprim Z primary clinical target volume;
GTVlymph Z lymph node gross target volume; GTVprim Z primary gross target volume; ROC Z receiver operating characteristics.
Average aeff values in the GTVprim, GTVlymph, CTVprim, and CTVlymph, respectively, and the fraction of negative aeff values were correlated with the
overall patient survival at 2 years. The results corresponding to sensitivity and specificity values >75% that are also statistically significant based on the P
value of the AUC are shown in italics. Those results that remained statistically significant after cross-validation with the “leave-one-out” method are
shown in bold italics.
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morphologic changes become visible. From this point of
view, PET could offer an insight into the early response to
treatment and thus open new directions for treatment
adaptation and for other strategies for treatment individu-
alization. It was the aim of the present study to explore this
aspect, taking into account not only changes in PET tracer
uptake but also the dose delivered and its distribution across
the tumor. The study was based on an early assessment of
tumor response to radiation treatment, to avoid possible
interference from the reduced number of surviving cells or
radiation-induced inflammatory processes that may be
induced at later timepoints. In this respect, the present study
differs from earlier attempts to characterize the in-treatment
response of the tumors after more than half of the radiation
treatment has been delivered (13, 14).
Another novelty of the present study was that it used a
voxel-based analysis of tumor response, taking into account
not only the initial regional uptake of the PET tracer but
also the local dose delivered to the tumor until the
intreatment PET investigation. Many other studies of the
topic (15-17, 19) have used global parameters to charac-
terize tumor uptake, and this reduced the sensitivity and
specificity of the identified trends, thus mirroring the large
intraindividual heterogeneity and different patterns
assessed for metabolic responders and nonresponders. The
definition of aeff used in this study implicitly entails that the
FDG uptake in the PTV decreases at the second timepoint
with respect to the level registered at the start of the
treatment (PET1>PET2). Hence, for negative aeff it is
possible that cell proliferative processes have a larger effect
than the cell depletion caused by the treatment. However, it
has to be mentioned that the numeric resulting values of aeff
expressed in Gy1 reported in this study cannot be used in a
straightforward calculation for determining the surviving
fraction of cells in the tumor using the linear quadraticmodel. The low values of aeff appear to confirm the pre-
viously postulated hypothesis of the dominant presence at
the time of the second FDG-PET image of cells taking up
the glucose-analog tracer but doomed to eventually die of
radiation damage (27). The determined aeff values would
also relate to the complexity and the dynamics of the tumor
microenvironment.
Given the size of the analyzed population, some con-
cerns were raised with respect to the risk of overfitting the
training data with the proposed model. Consequently, the
proposed approach was subjected to a cross-validation
analysis using the leave-one-out method to minimize this
risk. The analysis showed that the approach maintained
high sensitivity and specificity and even the statistical
significance for a subgroup of patients. These are promising
results and warrant a future external validation of the pro-
posed approach. Further sources of concern in applying the
method proposed in this study might be related to changes
in tumor size and shape during the time between the 2 PET
scans. However, the early assessment of the response as
proposed in this report might prevent very large changes.
Indeed, for the population of patients included in this study,
no large differences were observed, in either the volume or
displacement of the primary tumor or the lymph nodes (20).
However, further investigations are warranted and planned
to test the method for other tumor types and locations prone
to large geometric changes, such as the head and neck.
The strong correlation between the change in PET up-
take in the primary GTV and the overall survival at 2 years
shows the importance of controlling the primary disease to
improve patient survival. This is in contrast to the findings
of Hoang et al (27), who suggested that early treatment
response in head and neck cancers should be measured
quantitatively in nodal disease rather than the primary
tumor, although their findings might in fact reflect the use
of global parameters to characterize tumor response. Our
Volume 91  Number 2  2015 Tumor response evaluation with FDG-PET 383findings nevertheless suggest that overall control could be
improved through strategies aimed at increasing the control
of the primary tumors. Thus, the best results would
probably be obtained if poorly responding patients were
identified early during the treatment, given that salvage
therapies after completion of the initial treatment would fail
to improve the outcome.
Monitoring the early response of tumors is very efficient
for treatment adaptation and individualization and has the
potential to identify the candidates for more aggressive
strategies like dose escalation or combined therapies to
increase local control rates (28, 29). More advanced image
analysis approaches (30-32) are likely to further improve
the performance of such analyses. The voxel-based method
proposed in this study offers a practical approach toward
achieving this aim and also appears to have quite high
potential in identifying the patients responding to the
standard treatment, thus avoiding unnecessarily exposing
them to aggressive therapies that could increase the risk of
severe side effects.
Conclusions
The evaluation of the early response for the 26 NSCLC
cancer patients showed that it is feasible to determine
threshold parameters based on the effective radiosensitiv-
ities of the patients corresponding, respectively, to good and
poor responses.
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